US Patent 8,242,131: Scope, Claim Architecture, and Patent Landscape for Middle-of-the-Night Zolpidem Dosing
United States Patent 8,242,131 protects a method-of-treatment for middle-of-the-night insomnia where zolpidem is administered after the patient awakens, with dose timing and formulation properties engineered to allow return to sleep for less than 5 hours while enabling awakening about four hours after dosing without residual sedative effects. The claim set narrows treatment by patient age (non-elderly vs elderly), zolpidem dose ranges, absence of other hypnotics, and rapid exposure metrics including time-to-50% Cmax (T50% Cmax).
What is the core claim scope of US 8,242,131?
Independent claim 1 (non-elderly)
Claim 1 is the broadest independent anchor. It defines a treatment regimen plus performance conditions:
Protected population: “a non-elderly patient”
Indication/timing: “middle-of-the-night insomnia”
No prophylactic dosing: “without prophylactically administering zolpidem”
Dosage form: dosing with a pharmaceutical composition comprising:
- about 0.5 to about 4.75 mg zolpidem hemitartrate, or
- a molar equivalent amount of a pharmaceutically acceptable form of zolpidem
Exclusion: composition is “substantially free of other hypnotic agents”
Trigger: “patient awakens from sleep” and “desires to resume sleep for less than 5 hours”
Timing: “step of dosing … is performed after the patient awakens from sleep”
Residual effect performance: composition “permits the patient to awaken at a time about four hours after dosing without residual sedative effects”
Independent claim 12 (elderly)
Claim 12 mirrors claim 1 but changes the dosing window and patient age:
Protected population: “an elderly patient”
Dosage range: “about 1.5 to about 2.5 mg zolpidem hemitartrate” or molar equivalent zolpidem salt/form
All other regimen elements match claim 1:
- no prophylactic zolpidem
- dose after awakening
- substantially free of other hypnotics
- desires to resume sleep for less than 5 hours
- performance: awaken about four hours after dosing without residual sedative effects
How do dependent claims carve out formulation and pharmacokinetic boundaries?
The dependent claims add specific dose points, formulation excipients, and exposure/route characteristics that act as validity and enforcement handles.
Dose precision dependent claims
For non-elderly (claim 1 base):
- Claim 4: composition comprises about 3.0 mg to about 3.75 mg zolpidem hemitartrate
- Claim 8: composition comprises about 3.5 mg zolpidem hemitartrate
- Claim 22: a specific multi-factor embodiment combining:
- about 3.5 mg zolpidem hemitartrate
- salt form
- free of other hypnotic agents
- oral mucosa delivery
- patient resumes sleep within 30 minutes
- Claim 21: patient “has a normal capacity to metabolize zolpidem”
For elderly (claim 12 base):
- Claim 18: composition comprises about 1.75 mg zolpidem hemitartrate
- Claim 24: multi-factor embodiment combining:
- about 1.75 mg zolpidem hemitartrate
- salt form
- free of other hypnotic agents
- oral mucosa delivery
- resumes sleep within 30 minutes
Time-to-resleep and exposure-speed claims
- Claim 2 (non-elderly): resumes sleep within 30 minutes
- Claim 3 (non-elderly): “about 50% of the maximum plasma concentration (Cmax) … within about 30 minutes or less of dosing”
- Claim 13 (elderly): resumes sleep within 30 minutes
- Claim 14 (elderly): “about 50% of … Cmax … within about 30 minutes or less”
These claims tie enforceability to pharmacodynamic outcomes (return to sleep) and pharmacokinetic kinetics (time to 50% Cmax).
Route / site-of-action boundary
- Claim 5: composition provides delivery of zolpidem across the patient’s oral mucosa
- Claim 9 and 10: reiterate oral mucosa delivery for dependent embodiments
- Claim 15: reiterates oral mucosa delivery for elderly dependent claim set
- Claim 19: reiterates oral mucosa delivery for the 1.75 mg embodiment
- Claim 22 and 24: both require oral mucosa delivery
This route language is a high-leverage limitation: it distinguishes the invention from standard oral swallow regimens by anchoring the formulation to oral mucosal delivery.
Salt form and specific excipient
- Claim 6: zolpidem is in a salt form
- Claim 16: same for elderly
- Claim 7: composition further comprises sodium stearyl fumarate
The salt and excipient claims can support obviousness/nonobviousness arguments and provide narrower claim fallback positions.
Exclusion of other hypnotics
- Claim 1 already requires “substantially free of other hypnotic agents”
- Claim 11: composition is free of other hypnotic agents
- Claim 20: same for elderly
This creates a clear competitive “avoidance” corridor if a competitor’s product includes or co-formulates other hypnotics (though typical insomnia products do not co-formulate hypnotics).
What is the effective enforcement posture (how the claims are likely to be asserted)?
1) The invention is anchored in dosing after awakening
The key distinguishing regimen element is: dosing occurs after the patient awakens (no prophylactic bedtime dosing). This limits claim reach against conventional “take before sleep” insomnia products and policies.
2) The performance condition is time-bound to residual sedation
The claim requires that about four hours after dosing, the patient can awaken “without residual sedative effects.” In litigation, this becomes a fact-intensive element tied to clinical/PK/PD outcomes.
3) Formulation route limitations enable narrower infringement theories
The oral mucosa delivery limitations (claims 5, 9-10, 15, 19, 22, 24) provide a structured path to infringement allegations if the accused product uses a sublingual/buccal/oromucosal delivery design intended to enable rapid onset after middle-of-night awakening.
4) Pharmacokinetic speed is explicitly claimed
The “50% of Cmax within 30 minutes or less” claims are measurable. If an accused product provides slower systemic exposure, it may avoid those specific dependent claim scopes (even if independent claim elements remain in dispute).
Claim scope map (what is inside vs outside the patent)
| Element |
Present in independent claim 1 (non-elderly) |
Present in independent claim 12 (elderly) |
Dependent claims that tighten it |
| Middle-of-the-night insomnia |
Yes |
Yes |
Claims 2-3, 13-14 integrate performance |
| No prophylactic zolpidem |
Yes |
Yes |
Independent structure |
| Zolpidem dose range |
0.5 to 4.75 mg |
1.5 to 2.5 mg |
Claims 4, 8, 18 define points |
| Timing after awakening |
Yes |
Yes |
Independent structure |
| Desires to resume sleep < 5 hours |
Yes |
Yes |
Independent structure |
| “Substantially free” of other hypnotics |
Yes |
Yes |
Claims 11, 20 = “free” |
| Oral mucosa delivery |
Not in independent |
Not in independent |
Claims 5, 9-10, 15, 19, 22, 24 |
| Salt form |
Not in independent |
Not in independent |
Claims 6, 16 (salt form) |
| Exipient sodium stearyl fumarate |
Not in independent |
Not in independent |
Claim 7 |
| Resumes sleep within 30 min |
Dependent |
Dependent |
Claims 2, 13 |
| 50% Cmax within 30 min |
Dependent |
Dependent |
Claims 3, 14 |
| Awaken at about 4 hours without residual sedation |
Yes |
Yes |
Independent structure |
| Normal zolpidem metabolizer capacity |
Not in independent |
Not in independent |
Claim 21 |
What product class does this patent most closely align with?
This claim set aligns with rapid-onset, oromucosal zolpidem formulations designed for sleep-maintenance or middle-of-the-night dosing rather than pre-sleep sedation. The combination of:
- post-awakening dosing trigger,
- rapid systemic exposure (T50% Cmax),
- oral mucosa delivery,
- dose constraints by age,
is consistent with a product strategy that targets “get back to sleep” without next-morning impairment.
What is the patent landscape relevance for US 8,242,131?
Landscape conclusion from claim content
Without the file history, priority chain, prosecution record, and citation set, the landscape read must be derived directly from claim architecture:
US 8,242,131 is positioned as a formulation-and-use protection hybrid:
- Use: method treating middle-of-the-night insomnia after awakening without prophylactic administration.
- Formulation: oral mucosa delivery and salt/excipient features in dependent claims.
- Performance: return-to-sleep time and systemic exposure kinetics.
This means it tends to matter most for competitors developing:
- zolpidem products intended for “middle-of-the-night” dosing, not bedtime dosing, and/or
- oromucosal zolpidem dosage forms targeting fast onset and short window to return to sleep, and/or
- age-stratified dosing regimens with dose ranges in the claimed windows.
Risk mapping by development approach
| Competitor development approach |
Primary risk against US 8,242,131 |
Why |
| Bedtime zolpidem dosing (prophylactic) |
Lower vs independent claim elements |
Claim requires dosing after awakening and “without prophylactically administering zolpidem” |
| Middle-of-night zolpidem with standard swallowed tablets |
Medium |
Timing/indication elements still match; route limitations in dependent claims may reduce dependent claim exposure |
| Middle-of-night oromucosal zolpidem with fast exposure |
Higher |
Oral mucosa delivery + rapid Cmax kinetics claims create aligned infringement theories |
| Slower-onset zolpidem for mid-night |
Lower vs Cmax/T50 dependent claims |
Even if timing matches, speed-dependent limitations may be missed |
| Combination products with other hypnotics |
Potentially lower |
“Substantially free” / “free of other hypnotic agents” can be an avoidance point |
Where are the strongest “narrowing” pivots in this patent?
The strongest narrowing pivots are the ones that can be tested and designed around:
- Oral mucosa delivery (claims 5, 9-10, 15, 19, 22, 24)
- T50% Cmax within 30 minutes or less (claims 3, 14, plus in claims 22, 23, 25 by dependence chain)
- Dose point embodiments (3.5 mg for non-elderly; 1.75 mg for elderly)
- Sodium stearyl fumarate (claim 7)
- “Free of other hypnotic agents” (claims 11, 20)
These pivots can drive both:
- clearer infringement frameworks (measurable endpoints), and
- design-around decisions (change route, kinetics, dose, or excipient selection).
Key claim-by-claim technical interpretation (what the claim language forces)
Below is the practical “what it takes” interpretation for enforcement and freedom-to-operate analysis:
- Dosing is performed after awakening: any product labeling or protocol that instructs taking before sleep is outside the independent claim’s regimen trigger.
- No prophylactic zolpidem: the method requires the patient to be awakened first, then dosed.
- Awakening about four hours after dosing without residual sedative effects: clinical outcome or validated pharmacological proxy is required.
- “Substantially free” of other hypnotics: co-formulated hypnotic agents would undermine this element.
- Oral mucosa delivery: sublingual/buccal/oromucosal design is required for dependent claim coverage.
- Salt form: dependent claims require zolpidem in a salt form, not necessarily the specific hemitartrate for every embodiment depending on the claim text used.
- T50% Cmax: pharmacokinetic testing anchors dependent claim reach.
Key Takeaways
- US 8,242,131 protects a middle-of-the-night zolpidem method where dosing occurs after awakening and avoids prophylactic administration.
- Independent claim coverage is shaped by age (non-elderly vs elderly), zolpidem dose ranges, and a residual sedation constraint about four hours post-dose.
- Dependent claims tighten scope through oromucosal delivery, rapid exposure (T50% Cmax ≤ 30 min), return-to-sleep within 30 minutes, and specific excipient (sodium stearyl fumarate).
- The strongest design-around variables are dosing timing (before vs after awakening), route (oral mucosa delivery), and kinetic profile (T50% Cmax).
FAQs
-
Does US 8,242,131 cover bedtime zolpidem dosing?
No, the method requires dosing after the patient awakens and specifies treatment is “without prophylactically administering zolpidem.”
-
Which dependent claims create the most measurable infringement risk?
Claims tied to resumes sleep within 30 minutes and T50% Cmax within 30 minutes or less are measurable and can be tested in PK/PD studies.
-
Is oral mucosa delivery required in the independent claims?
No. Oral mucosa delivery appears in dependent claims (e.g., claims 5, 9-10, 15, 19, 22, 24).
-
What excipient is specifically called out?
Sodium stearyl fumarate is recited in claim 7.
-
How do the claim doses differ by age?
The independent claims set different zolpidem hemitartrate ranges: 0.5 to 4.75 mg for non-elderly (claim 1) versus 1.5 to 2.5 mg for elderly (claim 12).
References (APA)
[1] United States Patent 8,242,131.
